289677-11-8

Usage

Uses

Used in Pharmaceutical Industry:
Pregabalin is utilized as a therapeutic agent for the management of neuropathic pain, epilepsy, and generalized anxiety disorder. It functions by modulating the excessive neuronal activity associated with these conditions, providing relief and improving the quality of life for affected individuals.
Used in Pain Management:
Pregabalin is employed as an analgesic, particularly for neuropathic pain conditions. It helps in reducing pain signals transmitted to the brain by interacting with calcium channels, thus offering effective pain control.
Used in Epilepsy Treatment:
In the context of epilepsy, Pregabalin serves as an anticonvulsant medication. It helps to prevent seizures by stabilizing the electrical activity in the brain and reducing the likelihood of abnormal neuronal discharges.
Used in Anxiety Disorder Management:
Pregabalin is also used in the treatment of generalized anxiety disorder. It aids in reducing anxiety symptoms by dampening the hyperactivity of the central nervous system, thus promoting a sense of calm and well-being.

InChI:InChI=1/C16H19NO3/c18-15(9-8-12-6-7-12)17-14(11-20-16(17)19)10-13-4-2-1-3-5-13/h1-5,12,14H,6-11H2/t14-/m1/s1

Upstream product

• 5618-03-1 3-cyclopropanepropionic acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 186581-53-3 diazomethane 
• 104266-88-8 (4S)-4-benzyl-3-pent-4-enoyl-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties

A systematic examination of the central aromatic portion of the lead (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(1′H-spiro[indene-1,4′-piperidin]-1′-yl)butanamide (9) led to the discovery of a novel class of CCR2 receptor antagonists, which carry small alicyclic groups such as cyclopropyl, cylobutyl, or cyclopropylmethyl attached at C2 of the carbon backbone. The most potent compound discovered, namely (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-cyclopropyl-4-[(1R,3′R)-3′-methyl-1′H-spiro[indene-1,4′-piperidin]-1′-yl]butanamide (29), showed very high binding affinity (IC50 = 4 nM, human monocyte) and excellent selectivity toward other related chemokine receptors. The excellent pharmacokinetic profile of this new lead compound allows for extensive in vivo evaluation.

Novel small renin inhibitors containing 4,5- or 3,5-Dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2-P3 sites

Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P2-P3 sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesi

RENIN INHIBITING POLYHYDROXY-MONOAMIDES

Disclosed herein are compounds of the formula:R 1 CH 2 CH(X)CH(Y)CH(Z)CHR 2 C(O)NHCHR 3 CH(OH) CH(OH)R 4wherein R 1 is a terminal unit, for example lower cycloalkyl or phenyl; R 2 is, for example, an optionally substituted alkyl, cycloalkylme